AMERICAN CENTURY COMPANIES INC - NEVRO CORP ownership

NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

Quarter-by-quarter ownership
AMERICAN CENTURY COMPANIES INC ownership history of NEVRO CORP
ValueSharesWeighting
Q1 2022$260,000
-19.0%
3,618
-8.7%
0.00%
Q4 2021$321,000
-30.4%
3,9620.0%0.00%
Q3 2021$461,000
-30.0%
3,962
-0.4%
0.00%
Q2 2021$659,000
+18.7%
3,9770.0%0.00%
Q1 2021$555,000
-19.3%
3,9770.0%0.00%
-100.0%
Q4 2020$688,000
+24.4%
3,977
+0.2%
0.00%
Q3 2020$553,000
-0.2%
3,968
-14.5%
0.00%
-100.0%
Q2 2020$554,000
-64.6%
4,640
-70.3%
0.00%
-50.0%
Q1 2020$1,563,000
-78.3%
15,631
-82.7%
0.00%
-71.4%
Q2 2018$7,202,000
-17.5%
90,195
-10.4%
0.01%
-22.2%
Q1 2018$8,725,000
+56.3%
100,672
+24.5%
0.01%
+50.0%
Q4 2017$5,582,000
+14.2%
80,854
+50.4%
0.01%
+20.0%
Q3 2017$4,887,000
-88.8%
53,776
-90.8%
0.01%
-88.9%
Q2 2017$43,723,000
-32.2%
587,435
-14.7%
0.04%
-32.8%
Q1 2017$64,506,000
+16.4%
688,435
-9.7%
0.07%
+11.7%
Q4 2016$55,420,000
+21.1%
762,727
+74.0%
0.06%
+20.0%
Q3 2016$45,768,000
+155.2%
438,436
+80.3%
0.05%
+150.0%
Q2 2016$17,937,000
+305.3%
243,184
+209.1%
0.02%
+300.0%
Q1 2016$4,426,000
-21.7%
78,679
-6.1%
0.01%
-28.6%
Q4 2015$5,655,000
+27.3%
83,770
-12.5%
0.01%
+40.0%
Q3 2015$4,443,000
+25.8%
95,777
+45.8%
0.01%
+25.0%
Q2 2015$3,531,00065,6880.00%
Other shareholders
NEVRO CORP shareholders Q4 2020
NameSharesValueWeighting ↓
Tiger Eye Capital LLC 239,122$41,392,0008.25%
Integral Health Asset Management, LLC 88,000$15,233,0004.53%
Iron Triangle Partners LP 168,761$29,213,0003.79%
Eos Focused Equity Management, L.P. 14,002$2,424,0002.37%
PFM Health Sciences, LP 311,940$53,997,0001.90%
Perceptive Advisors 977,565$169,217,0001.82%
Rock Springs Capital Management LP 395,000$68,375,0001.45%
Lisanti Capital Growth, LLC 54,302$9,400,0001.30%
HealthCor Management, L.P. 156,046$27,012,0001.04%
FRED ALGER MANAGEMENT, LLC 2,136,612$369,848,0000.96%
View complete list of NEVRO CORP shareholders